Wells Fargo Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has initiated coverage on Arcus Biosciences with an Overweight rating and set a price target of $29.
October 08, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Arcus Biosciences with an Overweight rating and a price target of $29, indicating a positive outlook.
The Overweight rating and $29 price target from Wells Fargo suggest a positive outlook for Arcus Biosciences, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100